FLT3 inhibitors for the treatment of acute myeloid leukemia.

Article

FLT3 inhibitors for the treatment of acute myeloid leukemia.

Clinical advances in hematology & oncology : H&O - 1 Jun 2010

Wiernik Peter H

Abstract excerpt

The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and cells of the immune system, is frequently mutated in patients with acute myeloid leukemia (AML). FLT3 is, therefore, a potential therapeutic target in AML. Recently, FLT3...

Topics

Antineoplastic Agents
Clinical Trials as Topic
Enzyme Inhibitors
Humans
Leukemia, Myeloid, Acute
Mutation
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.